Pharmaceutics 2013, 5(1), 179-200; doi:10.3390/pharmaceutics5010179
Article

Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan Statistic

1,2,* email, 3email, 3email, 1,2email, 1email, 1,2email, 1email, 2,4email, 5,6email, 2,7email, 2,8email, 2,9email, 2,10email, 2,11email, 2,12email, 2,6email, 2,13email and 3email
Received: 6 November 2012; in revised form: 1 March 2013 / Accepted: 4 March 2013 / Published: 14 March 2013
(This article belongs to the Special Issue Drug Safety and Pharmacovigilance)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Background: Drug adverse event (AE) signal detection using the Gamma Poisson Shrinker (GPS) is commonly applied in spontaneous reporting. AE signal detection using large observational health plan databases can expand medication safety surveillance. Methods: Using data from nine health plans, we conducted a pilot study to evaluate the implementation and findings of the GPS approach for two antifungal drugs, terbinafine and itraconazole, and two diabetes drugs, pioglitazone and rosiglitazone. We evaluated 1676 diagnosis codes grouped into 183 different clinical concepts and four levels of granularity. Several signaling thresholds were assessed. GPS results were compared to findings from a companion study using the identical analytic dataset but an alternative statistical method—the tree-based scan statistic (TreeScan). Results: We identified 71 statistical signals across two signaling thresholds and two methods, including closely-related signals of overlapping diagnosis definitions. Initial review found that most signals represented known adverse drug reactions or confounding. About 31% of signals met the highest signaling threshold. Conclusions: The GPS method was successfully applied to observational health plan data in a distributed data environment as a drug safety data mining method. There was substantial concordance between the GPS and TreeScan approaches. Key method implementation decisions relate to defining exposures and outcomes and informed choice of signaling thresholds.
Keywords: pharmacovigilance; drug safety surveillance; adverse events data mining; gamma Poisson shrinkage; tree-based scan statistic
PDF Full-text Download PDF Full-Text [262 KB, Updated Version, uploaded 15 March 2013 14:53 CET]
The original version is still available [271 KB, uploaded 14 March 2013 15:41 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Brown, J.S.; Petronis, K.R.; Bate, A.; Zhang, F.; Dashevsky, I.; Kulldorff, M.; Avery, T.R.; Davis, R.L.; Chan, K.A.; Andrade, S.E.; Boudreau, D.; Gunter, M.J.; Herrinton, L.; Pawloski, P.A.; Raebel, M.A.; Roblin, D.; Smith, D.; Reynolds, R. Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan Statistic. Pharmaceutics 2013, 5, 179-200.

AMA Style

Brown JS, Petronis KR, Bate A, Zhang F, Dashevsky I, Kulldorff M, Avery TR, Davis RL, Chan KA, Andrade SE, Boudreau D, Gunter MJ, Herrinton L, Pawloski PA, Raebel MA, Roblin D, Smith D, Reynolds R. Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan Statistic. Pharmaceutics. 2013; 5(1):179-200.

Chicago/Turabian Style

Brown, Jeffrey S.; Petronis, Kenneth R.; Bate, Andrew; Zhang, Fang; Dashevsky, Inna; Kulldorff, Martin; Avery, Taliser R.; Davis, Robert L.; Chan, K. A.; Andrade, Susan E.; Boudreau, Denise; Gunter, Margaret J.; Herrinton, Lisa; Pawloski, Pamala A.; Raebel, Marsha A.; Roblin, Douglas; Smith, David; Reynolds, Robert. 2013. "Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan Statistic." Pharmaceutics 5, no. 1: 179-200.


Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert